Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
Antibody drugs have fewer and fewer adverse reactions because of their high specificity. Therefore, therapeutic antibody has become the predominant class of new drugs developed in recent years. Basically, the whole research and development process of antibody drugs will take 10 years, from the initial identification of targets, to screening of therapeutic antibody candidates for pre-clinical studies, to enter clinical phase Ⅰ/ Ⅱ / Ⅲ trials, and then to complete the final declaration of NDA (new drug application). Throughout the whole process of antibody drug development, therapeutic antibody discovery service is the very beginning of antibody-based drug discovery, and it is crucial as well.
CUSABIO has been working on the development and production of proteins and antibodies for more than 16 years and successfully screened 100+ therapeutic antibody candidates for pharmaceutical companies already, many of which have entered the CMC or IND phases. For some challenging targets, including CLDN18.2, CLDN6, CCR8, SSTR2, DLL3, LY6G6D, ROR1, SEMA4D, GPC3, CD16A and so on, we not only successfully had produced antigens, but also successfully screened corresponding recombinant antibodies already. CUSABIO has 3 platforms for production of transmembrane proteins. Mostly, we have completed 30+ projects of screening services targeting multi-pass transmembrane proteins. So we can confidently promise that CUSABIO has rich experiences in therapeutic antibody discovery service targeting multi-pass transmembrane protein, and we can offer the therapeutic antibody discovery service to you as risk-free, we can promise that we will not charge any fee if we failed in screening.
CUSABIO can provide a one-stop solution from targets to therapeutic antibody candidates to accelerate the entire development process for you.
CUSABIO has 16 years of experience in recombinant protein expression and can provide one-stop services from gene synthesis, vector construction to protein expression and purification. Based on the traditional five recombinant protein expression systems (E. coli, Yeast, Insect Baculovirus, Mammalian cell and In vitro E.coli systems), CUSABIO has now launched four dominant protein expression platforms for drug target proteins, namely Virus-like Particles (VLPs), Detergent Micelle, Nanodisc and Nanoparticle platforms. More interesting reading related Virus-like Particles, Detergent Micelle, Nanodisc and Nanoparticle platforms>>
Reference antibody refers to drug control antibody. It is usually used to detect the antigen or stable cell line to determine whether the antigen or stable cell line is qualified. In addition, It also acts as a control to screen antibody in FACS. The priority order of reference antibody sequence reference is as follows: marketed antibody drugs, clinical stage (Ⅰ-Ⅲ) antibody drugs, preclinical stage antibody drugs, and FACS antibodies.
Stable cell line refers to a cell line that continuously and stably expresses or interferes with the expression of a specific gene through stable transduction. In the field of antibody development, stable transfected cell lines can be used as immunogens to stimulate specific immune responses in animals, and can target multiple transmembrane proteins. In addition, stable transfected cell lines are widely used in antibody binding and functional screening experiments. CUSABIO can provide stable cell line construction service, and the specific service contents are as follows:
| Lentivirus Packaging and Construction of Stable Cell Service | |||
| No. | Process | Service Items | Service Cycle |
|---|---|---|---|
| 1 | Construction of recombinant plasmid | Codon optimization, full gene synthesis, construction of lentiviral expression vector, large-scale extraction of plasmids | 2-3 weeks |
| 2 | Lentiviral packaging | Co-transform the expression vector and helper plasmid into 293T cells for lentivirus packaging | 1-2 weeks |
| 3 | Cell pool screening and verification | Screen the positive cells with the corresponding screening agent, and detect the expression level of the cell pool | 1-2 weeks |
| 4 | Monclonal stable cell screening and verification | Plate single cells and verify the expression of monclonal stable cell | 3-4 weeks |
| 5 | Monclonal stable cell cryopreservation and QC | Monclonal stable cell expansion culture, cryopreservation, resuscitation detection viability rate and microbial contamination | 1-2 weeks |
| Total time | 8-12 weeks | ||
CUSABIO has 16 years of rich experience in the development of hybridoma monoclonal antibodies with mature technical routes, stable and reliable product quality and high success rate. The initial positive rate is as high as about 20%-40%, and the positive rate in FACS is about 10%-20%, which can meet the needs of different types of customers.
CUSABIO conducts antibody functional testing based on customer requirements, including antigen ELISA, cell-based FACS, antigen SPR, and antibody Binning assays. The assays of ELISA and SPR mainly evaluate the binding activity and affinity between antigen and correspoding antibody. The assay of FACS is used to verify the binding activity between the screened antibody and the stable cell line. The purpose of Binning assay is to identify whether the screened antibody and reference antibody recognize the same epitope.
CUSABIO is going to express the top postitive clones for fruther validation according to customers' requirement. CUSABIO can guarantee the produced antibody can be succeeded in FACS with stable cell lines. Top 50 sequences or even more could be delivered based on customers' requirement.
